Johnson & Johnson MedTech (NYSE: JNJ) today announced the first completed commercial case with its Varipulse platform in ...

The article " Johnson & Johnson Stock: Setting the Stage for 2025 Highs " first appeared on MarketBeat.

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

The Liberia Petroleum Refining Corporation (LPRC), under its new Managing Director, Amos Tweh, has implemented key measures to revitalize Liberia’s oil and gas sector and alleviate the economic strain ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), retaining the price ...

Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer ...